Loading...

OpGen

DB:6501
Snowflake Description

Mediocre balance sheet with limited growth.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
6501
DB
$10M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

OpGen, Inc., a precision medicine company, engages in developing molecular information products and services to combat infectious diseases in the United States and internationally. The last earnings update was 49 days ago. More info.


Add to Portfolio Compare Print
  • OpGen has significant price volatility in the past 3 months.
6501 Share Price and Events
7 Day Returns
-11.7%
DB:6501
0.3%
DE Biotechs
2.3%
DE Market
1 Year Returns
-70.5%
DB:6501
-7.9%
DE Biotechs
-7.2%
DE Market
6501 Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
OpGen (6501) -11.7% -54.3% -68.1% -70.5% - -
DE Biotechs 0.3% 3.1% -6.5% -7.9% 43.5% 7.6%
DE Market 2.3% 3.1% 8.8% -7.2% 9.3% 12.3%
1 Year Return vs Industry and Market
  • 6501 underperformed the Biotechs industry which returned -7.9% over the past year.
  • 6501 underperformed the Market in Germany which returned -7.2% over the past year.
Price Volatility
6501
Industry
5yr Volatility vs Market

Value

 Is OpGen undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for OpGen. This is due to cash flow or dividend data being unavailable. The share price is €0.466.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for OpGen's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are OpGen's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:6501 PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in USD $-2.22
NasdaqCM:OPGN Share Price ** NasdaqCM (2019-04-17) in USD $0.56
Europe Biotechs Industry PE Ratio Median Figure of 30 Publicly-Listed Biotechs Companies 23.37x
Germany Market PE Ratio Median Figure of 422 Publicly-Listed Companies 19.43x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of OpGen.

DB:6501 PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqCM:OPGN Share Price ÷ EPS (both in USD)

= 0.56 ÷ -2.22

-0.25x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • OpGen is loss making, we can't compare its value to the Europe Biotechs industry average.
  • OpGen is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does OpGen's expected growth come at a high price?
Raw Data
DB:6501 PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -0.25x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 4 Analysts
-2.5%per year
Europe Biotechs Industry PEG Ratio Median Figure of 22 Publicly-Listed Biotechs Companies 1.31x
Germany Market PEG Ratio Median Figure of 272 Publicly-Listed Companies 1.56x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for OpGen, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on OpGen's assets?
Raw Data
DB:6501 PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in USD $0.38
NasdaqCM:OPGN Share Price * NasdaqCM (2019-04-17) in USD $0.56
Germany Biotechs Industry PB Ratio Median Figure of 15 Publicly-Listed Biotechs Companies 3.89x
Germany Market PB Ratio Median Figure of 570 Publicly-Listed Companies 1.87x
DB:6501 PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqCM:OPGN Share Price ÷ Book Value per Share (both in USD)

= 0.56 ÷ 0.38

1.46x

* Primary Listing of OpGen.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • OpGen is good value based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess OpGen's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. OpGen has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is OpGen expected to perform in the next 1 to 3 years based on estimates from 4 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
-2.5%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is OpGen expected to grow at an attractive rate?
  • Unable to compare OpGen's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.
Growth vs Market Checks
  • Unable to compare OpGen's earnings growth to the Germany market average as it is expected to be loss making during the next 1-3 years.
  • OpGen's revenue growth is expected to exceed the Germany market average.
Annual Growth Rates Comparison
Raw Data
DB:6501 Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:6501 Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 4 Analysts -2.5%
DB:6501 Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 4 Analysts 40.8%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 47.6%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 26.1%
Germany Market Earnings Growth Rate Market Cap Weighted Average 11.7%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:6501 Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 4 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:6501 Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2020-12-31 7 -15 -14 3
2019-12-31 4 -13 -13 4
DB:6501 Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2018-12-31 3 -11 -13
2018-09-30 3 -11 -13
2018-06-30 3 -12 -13
2018-03-31 3 -12 -13
2017-12-31 3 -14 -15
2017-09-30 3 -16 -17
2017-06-30 3 -16 -19
2017-03-31 4 -18 -20
2016-12-31 4 -17 -19
2016-09-30 4 -16 -19
2016-06-30 5 -19 -19
2016-03-31 4 -16 -19

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • OpGen is not considered high growth as it is expected to be loss making for the next 1-3 years.
  • OpGen's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:6501 Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 4 Analyst Estimates (S&P Global) See Below

All data from OpGen Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:6501 Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2020-12-31 -0.78 -0.59 -0.90 3.00
2019-12-31 -0.88 -0.80 -0.99 4.00
DB:6501 Past Financials Data
Date (Data in USD Millions) EPS *
2018-12-31 -2.22
2018-09-30 -2.76
2018-06-30 -3.60
2018-03-31 -5.80
2017-12-31 -9.80
2017-09-30 -13.83
2017-06-30 -19.20
2017-03-31 -23.72
2016-12-31 -27.59
2016-09-30 -32.08
2016-06-30 -37.07
2016-03-31 -43.94

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if OpGen will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess OpGen's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
OpGen has a total score of 2/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has OpGen performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare OpGen's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • OpGen does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare OpGen's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare OpGen's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
OpGen's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from OpGen Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:6501 Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 2.95 -13.37 8.60
2018-09-30 3.18 -12.60 8.28
2018-06-30 3.37 -12.61 8.10
2018-03-31 3.29 -13.49 8.51
2017-12-31 3.21 -15.42 9.46
2017-09-30 3.23 -17.21 10.56
2017-06-30 3.24 -18.79 11.56
2017-03-31 3.72 -19.97 12.27
2016-12-31 4.03 -19.50 12.13
2016-09-30 4.35 -19.47 12.72
2016-06-30 4.57 -19.29 12.43
2016-03-31 3.76 -19.34 11.39
2015-12-31 3.16 -17.60 10.14
2015-09-30 2.95 -14.44 7.95 -3.08
2015-06-30 2.80 -11.56 6.21
2015-03-31 3.50 -7.75 4.95
2014-12-31 4.13 -6.30 4.37
2014-09-30 3.62 -8.83 4.39 3.08
2013-12-31 2.41 -15.51 5.82
2012-12-31 5.80 -14.21 6.75

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if OpGen has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if OpGen has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if OpGen improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess OpGen's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
OpGen has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is OpGen's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up OpGen's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • OpGen is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • OpGen's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of OpGen's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 3.1x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from OpGen Company Filings, last reported 3 months ago.

DB:6501 Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 3.31 1.90 4.57
2018-09-30 4.03 1.96 4.74
2018-06-30 6.40 1.95 7.43
2018-03-31 9.30 1.48 10.29
2017-12-31 1.40 1.30 1.85
2017-09-30 3.76 1.38 4.85
2017-06-30 -2.14 1.98 0.21
2017-03-31 0.55 1.28 1.67
2016-12-31 3.17 1.35 4.12
2016-09-30 3.28 1.49 4.26
2016-06-30 7.94 1.63 8.03
2016-03-31 3.25 1.51 3.97
2015-12-31 7.49 1.57 7.81
2015-09-30 11.94 1.55 11.19
2015-06-30 8.83 0.33 10.22
2015-03-31 -4.08 3.79 0.63
2014-12-31 -3.50 3.24 0.75
2014-09-30 -2.08 1.77 0.78
2013-12-31 0.17 0.35 1.40
2012-12-31 8.15 0.18 7.12
  • OpGen's level of debt (57.3%) compared to net worth is high (greater than 40%).
  • The level of debt compared to net worth has been reduced over the past 5 years (222.1% vs 57.3% today).
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • OpGen has less than a year of cash runway based on current free cash flow.
  • OpGen has less than a year of cash runway if free cash flow continues to reduce at historical rates of -13.3% each year.
X
Financial health checks
We assess OpGen's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. OpGen has a total score of 3/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is OpGen's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from OpGen dividends.
If you bought €2,000 of OpGen shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate OpGen's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate OpGen's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:6501 Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 4 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 0.9%
Germany Market Average Dividend Yield Market Cap Weighted Average of 325 Stocks 3.1%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.4%
Germany Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:6501 Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2020-12-31
2019-12-31

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as OpGen has not reported any payouts.
  • Unable to verify if OpGen's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of OpGen's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as OpGen has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess OpGen's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can OpGen afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. OpGen has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of OpGen's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Evan Jones
COMPENSATION $394,209
AGE 61
TENURE AS CEO 5.5 years
CEO Bio

Mr. Evan Jones, M.B.A., serves as Executive Chairman of jVEN Capital, LLC. Mr. Jones founded and has served as Managing Member of jVEN Capital, LLC since July 2007. Mr. Jones has been Chief Executive Officer and Chairman of the Board at OpGen, Inc. since October 2013 and served as its President from October 2013 to April 2015. He served as an Interim Chief Executive Officer at OpGen, Inc. from December 2009 to June 2010 and served as its Chairman since September 1995 and Director since July 1990. He served as the Chief Executive Officer from July 1990 to November 22, 2006 and President from July 1990 to June 1999 at QIAGEN Gaithersburg Inc., which he founded in July 1990. Mr. Jones was a Co-Founder of Digene Corporation and was its Chairman from 1995 to 2007, Chief Executive Officer from 1990 to 2006 and President from 1990 to 1999. From 1988 to September 1990, he served as the President at Neomorphics, Inc. From 1987 to 1990, He served as an Associate at CW Group, Inc. He has also worked at Applied Biosystems, Inc. From 1983 to 1987, he was employed at Perkin-Elmer Corporation. He also serves on the Board of Directors of Research!America. Mr. Jones served as a member of the board of directors of CAS Medical Systems, Inc. (NASDAQ: CASM), a developer of patient vital signs monitoring products and technologies, from June 2008 to October 2013. He serves as the Chairman of the Campaign for Public Health and served as the Chairman of the Board of Children's Research Institute at the Children's National Medical Center. He serves as Vice Chairman of Children's National Health System. He served as an Independent Director at Foundation Medicine, Inc. from January 2013 to July 31, 2018. He has been a Director of Veracyte, Inc. since February 2008. He is a Director at OpGen since 2009. He serves as a Member of the Board of Directors of the Children’s Research Institute where he was Chairman and Children’s National Medical Center and the Board of Visitors of the University Of Maryland College Of Life Sciences. He served as a Director of Fluidigm Corporation from April 4, 2011 to August 1, 2017. He served as the Chairman of Signature Genomic Laboratories, LLC from June 2008 to May 2010. He has more than 30 years of operating and investment experience in the life sciences industry, where he founded or helped start numerous life sciences companies. He received an M.B.A. from Wharton School at University of Pennsylvania and a B.A. in Biochemistry/Biotechnology from the University of Colorado.

CEO Compensation
  • Evan's compensation has been consistent with company performance over the past year.
  • Evan's remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the OpGen management team in years:

5
Average Tenure
59
Average Age
  • The average tenure for the OpGen management team is over 5 years, this suggests they are a seasoned and experienced team.
Management Team

Evan Jones

TITLE
Chairman & CEO
COMPENSATION
$394K
AGE
61
TENURE
5.5 yrs

Tim Dec

TITLE
CFO & Corporate Secretary
COMPENSATION
$314K
AGE
59
TENURE
3.9 yrs

Vadim Sapiro

TITLE
Chief Information Officer
COMPENSATION
$314K
AGE
47
TENURE
7.3 yrs

Michael Farmer

TITLE
Vice President of Marketing

Terry Walker

TITLE
Senior Vice President of Research & Development
AGE
59
TENURE
4.5 yrs
Board of Directors Tenure

Average tenure and age of the OpGen board of directors in years:

3.4
Average Tenure
63
Average Age
  • The tenure for the OpGen board of directors is about average.
Board of Directors

Evan Jones

TITLE
Chairman & CEO
COMPENSATION
$394K
AGE
61
TENURE
8.6 yrs

Misti Ushio

TITLE
Independent Director
COMPENSATION
$45K
AGE
47
TENURE
7.1 yrs

Tina Nova Bennett

TITLE
Director
COMPENSATION
$35K
AGE
64
TENURE
2 yrs

Don Elsey

TITLE
Director
AGE
64
TENURE
0.2 yrs

Tim Harris

TITLE
Independent Director
COMPENSATION
$36K
AGE
67
TENURE
4 yrs

Attila Lorincz

TITLE
Member of Clinical Advisory Board
AGE
63

James Snyder

TITLE
Member of Clinical Advisory Board

David Rubin

TITLE
Independent Director
AGE
53
TENURE
3.8 yrs

Debra Goff

TITLE
Member of Clinical Advisory Board
TENURE
3.1 yrs

Stefan Riedel

TITLE
Member of Clinical Advisory Board
TENURE
3.1 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
01. Apr 19 Buy jVEN Capital, LLC Company 28. Mar 19 28. Mar 19 417,000 €0.53 €222,928
X
Management checks
We assess OpGen's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. OpGen has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

OpGen, Inc., a precision medicine company, engages in developing molecular information products and services to combat infectious diseases in the United States and internationally. The company utilizes molecular diagnostics and informatics to help combat infectious diseases. It also helps clinicians with information about life threatening infections, enhance patient outcomes, and decrease the spread of infections caused by multidrug-resistant microorganisms. The company’s products include Acuitas AMR Gene Panel, a vitro diagnostic test for the detection and identification of various bacterial nucleic acids and genetic determinants of antimicrobial resistance in urine specimens or bacterial colonies isolated from urine and other body sites; and QuickFISH and PNA FISH products, which are FDA-cleared and CE-marked diagnostic test designed to detect antimicrobial- resistant pathogens. In addition, it offers Acuitas Lighthouse informatics systems, a cloud-based HIPAA compliant informatics offerings, which combine clinical lab test results with patient and hospital information, and provide analytics and insights to enable manage MDROs in the hospital and patient care environment. The company was incorporated in 2001 and is headquartered in Gaithersburg, Maryland.

Details
Name: OpGen, Inc.
6501
Exchange: DB
Founded: 2001
$8,744,230
17,645,720
Website: http://www.opgen.com
Address: OpGen, Inc.
708 Quince Orchard Road,
Suite 205,
Gaithersburg,
Maryland, 20878,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqCM OPGN Common Stock Nasdaq Capital Market US USD 05. May 2015
DB 6501 Common Stock Deutsche Boerse AG DE EUR 05. May 2015
Number of employees
Current staff
Staff numbers
47
OpGen employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/17 23:53
End of day share price update: 2019/04/17 00:00
Last estimates confirmation: 2019/04/15
Last earnings filing: 2019/02/27
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.